BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Core Viewpoint - The market anticipates BioCryst Pharmaceuticals (BCRX) will report a year-over-year increase in earnings driven by higher revenues when it releases its results for the quarter ended December 2024 [1] Financial Expectations - The upcoming earnings report is expected to be released on February 24, 2025, with a consensus estimate of a quarterly loss of $0.06 per share, reflecting a year-over-year change of +78.6$130.8 million, which is a 40% increase from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial estimates during this period [4] - The Most Accurate Estimate for BioCryst is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -7.14%, suggesting a bearish outlook from analysts [10] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from the consensus estimate, but its predictive power is more significant for positive readings [7] - A positive Earnings ESP combined with a strong Zacks Rank (1-3) has historically led to a positive surprise nearly 70% of the time [8] Historical Performance - In the last reported quarter, BioCryst was expected to post a loss of $0.07 per share and did so, resulting in no surprise [12] - Over the last four quarters, the company has beaten consensus EPS estimates two times [13] Industry Comparison - Another player in the Zacks Medical - Drugs industry, Ardelyx (ARDX), is expected to post earnings of$0.02 per share for the same quarter, indicating a year-over-year change of +116.7% and revenues expected to be $111.19 million, up 223.6% from the previous year [17] - Ardelyx has an Earnings ESP of 48.49%, suggesting a higher likelihood of beating the consensus EPS estimate [18]